J2H-2002 / J2HBiotech - LARVOL DELTA

J2H, oral presentation of preclinical results of non-small cell lung cancer drug candidates [Google translation] (HIT News) - "J2H Biotech...announced on the 7th that it orally presented the preclinical results of J2H-2002 (development code name)', a non-small cell lung cancer drug candidate, at 'AIMECS 2023', an Asian international pharmaceutical chemistry society....'EGFR C797S is a cancer that occurs when the 797th amino acid of EGFR is modified. It was found to inhibit cancer growth by up to 95% in triple mutation lung cancer animal models (CDX and PDX) including . No side effects such as weight loss were observed'....'Starting with the results of this preclinical study, we are planning various studies, including co-administration of J2H-2002 with existing anticancer drugs. 'After completing, we plan to start clinical trials in the first half of next year'."

New trial • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor